References
1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.
2. Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al.
Rapid point-of-care testing for SARS-CoV-2 in a community screening
setting shows low sensitivity. Public Health. 2020;182:170–2.
3. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D,
Zambrano-Achig P, Campo R del, Ciapponi A, et al. False-negative results
of initial RT-PCR assays for COVID-19: a systematic review. medRxiv.
2020 (ref 2020.04.16.20066787).
4. NICE. FebriDx for C-reactive protein and Myxovirus virus resistance
protein A testing in primary care: A testing in primary care Medtech
innovation briefing. 2017. London: NICE.
5. Karim N, Ashraf MZ, Naeem M, Anwar T, Aung H, Mallik S, et al.
Utility of FebriDx in early identification of possible COVID19
infection. Res Sq 2020; doi 10.21203/rs.3.rs-25802/v1.
6. Brendish NJ, Poole S, Naidu V V, Mansbridge C, Norton N, Wheeler H,
et al. Real-world diagnostic accuracy of a host response point-of-care
test in hospitalised patients with suspected COVID-19. Lancet 2020. SSRN
pre-print: https://dx.doi.org/10.2139/ssrn.3582747.
7. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M,
et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related
Coronavirus-2: A Narrative Review. Ann Intern Med 2020;13:13.
8. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et
al. Virological assessment of hospitalized patients with COVID-2019.
Nature. 2020; 581: 465–469.
9. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody
responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.
Clin Infect Dis 2020;28.
10. Guo L, Ren L, Yang S, Xiao M, Chang, Yang F, et al. Profiling Early
Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin
Infect Dis 2020;21.
11. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick L,
Rattigan SM, et al. A systematic review of antibody mediated immunity to
coronaviruses: antibody kinetics, correlates of protection, and
association of antibody responses with severity of disease. medRxiv 2020
(ref 2020.04.14.20065771).
12. Spiegel M, Weber F. Inhibition of cytokine gene expression and
induction of chemokine genes in non-lymphatic cells infected with SARS
coronavirus. Virol J. 2006; 29(3):17.
13. Beard K, Chan C, Mills S, Poole S, Brendish N, Tristan William C.
Evaluation of the Febridx Host Response Point-of-Care Test to
Differentiate Viral From Bacterial Etiology in Adults Hospitalized with
Acute Respiratory Illness During Influenza Season. Open Forum Infect
Dis. 2019;6(Suppl 2):2019.
14. Sambursky R, Shapiro N. Evaluation of a combined MxA and CRP
point-of-care immunoassay to identify viral and/or bacterial immune
response in patients with acute febrile respiratory infection. Eur Clin
Respir J. 2015;2(1):28245.
15. Self W, Rosen J, Sharp S, Filbin M, Hou P, Parekh A, et al.
Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses
to Viral and Bacterial Upper Respiratory Infections. J Clin Med. 2017;
6(10): 94.
16. Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, et al. A
prospective, multi-centre US clinical trial to determine accuracy of
FebriDx point-of-care testing for acute upper respiratory infections
with and without a confirmed fever. Ann Med. 2018; 50(5):420-429.
17. FIND. SARS-CoV2 diagnostics: performance data. 2020. Available from:
https://www.finddx.org/covid-19/dx-data/ [accessed 02/06/2020]